The pathogenesis of dengue virus infection in patients with sickle cell disease
Recruiting
- Conditions
- break-bone fever10047438dengue10018902
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 26
Inclusion Criteria
Adult patient with sickle cell disease (HbSS genotype)
Exclusion Criteria
Blood transfusion in the preceding three months.
Painful vaso-occlusive crisis/acute chest syndrome/stroke or other acute complications in the preceding 2 weeks.
Current use of hydroxyurea.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>From the supernatant of the HUVECs which were incubated with the DENV infected<br /><br>PBMCs we would like to investigate the following parameters:<br /><br>Virus titre<br /><br>Inflammatory markers (TNF-a, IL-1β)<br /><br>Coagulation markers(TF, sTM) </p><br>
- Secondary Outcome Measures
Name Time Method <p>-</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link dengue virus infection to sickle cell disease pathogenesis?
How does dengue virus replication differ in sickle cell disease patients compared to standard-of-care treatment groups?
Which biomarkers are associated with severe dengue outcomes in individuals with sickle cell disease?
What are the potential adverse events of dengue virus infection in sickle cell disease patients and how can they be managed?
Are there any combination therapies or drug targets being explored for dengue treatment in sickle cell disease populations?